Roth MKM resumed coverage of aTyr Pharma with a Buy rating and $9 price target. Enzofitimod, which is enrolling patients in a Phase 3 trial in pulomonary sarcoidosis, is expected to have a differentiated product profile compared to corticosteroids, immunosuppressants, and immunomodulators with high efficacy and a comparatively better side effect profile, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LIFE:
- aTyr Pharma provides plans regarding initiation of Phase 2 study of efzofitimod
- aTyr Pharma 22.2M share Spot Secondary priced at $2.25
- aTyr Pharma Announces Commencement of Public Offering of Common Stock
- aTyr Pharma announces common stock offering, no amount given
- aTyr Pharma announces achievement of milestone by partner Kyorin Pharmaceutical
